Gilead Sciences Net Worth (Updated 2026).

Gilead Sciences, a name now synonymous with medical innovation, began its journey in 1987 as a small biotechnology company in Foster City, California. Founded by Michael Riordan and Donald R. Francis, the company was initially focused on developing therapies for viral diseases, a field that was largely unexplored at the time.

Gilead’s breakthrough came in the late 1990s with the development of its first drug, Zidovudine, more commonly known as AZT. This drug, used to treat HIV/AIDS, was a groundbreaking achievement in the fight against the disease. Its success not only established Gilead as a leader in antiviral therapy but also paved the way for the company’s future innovations.

Gilead Sciences’ Current Net Worth (2025)

As of 2025, Gilead Sciences’ market capitalization is estimated to be around $180 billion. This figure is based on the latest available information and reflects the company’s significant presence in the biopharmaceutical industry.

Career

Gilead Sciences, founded in 1987, has grown from a small startup to a global leader in biopharmaceuticals. The company is known for its pioneering work in HIV/AIDS treatment, with drugs like Truvada and Atripla. It has also made significant strides in hepatitis C therapy, with Harvoni and Epclusa, contributing to a 95% cure rate worldwide.

Other Ventures

Beyond HIV/AIDS and hepatitis C, Gilead has expanded its portfolio to include treatments for inflammation, cancer, and respiratory diseases. It has also invested in research and development for potential therapies against COVID-19, demonstrating its commitment to addressing global health challenges.

Assets

Gilead’s assets include a robust pipeline of drugs in various stages of clinical development, a strong intellectual property portfolio, and a network of manufacturing facilities worldwide. Its portfolio of marketed drugs generated $22.4 billion in revenue in 2020, highlighting the value of its assets.

Annual Income

In 2020, Gilead Sciences reported total revenue of $22.4 billion, a 16% increase from the previous year. This growth can be attributed to the strong performance of its HIV and hepatitis C franchises, as well as contributions from its cancer and inflammation portfolios.

Frequently Asked Questions about  Gilead Sciences

Frequently Asked Questions: Gilead Sciences Net Worth

1. What is Gilead Sciences’ primary business?

Gilead Sciences is primarily a biopharmaceutical company that discovers, develops, and commercializes therapeutics for the treatment of life-threatening diseases, with a focus on HIV, hepatitis C, and cancer.

2. When was Gilead Sciences founded?

Gilead Sciences was founded in 1987 and is headquartered in Foster City, California.

3. Who is the current CEO of Gilead Sciences?

The current CEO of Gilead Sciences is Daniel O’Day, who took over the position in March 2019.

4. What are some of Gilead Sciences’ most well-known drugs?

Some of Gilead Sciences’ most well-known drugs include Truvada (for HIV prevention and treatment), Harvoni (for hepatitis C), and Viread (for HIV treatment and prevention).

5. How many employees does Gilead Sciences have?

As of 2021, Gilead Sciences has approximately 11,000 employees worldwide.

6. What is Gilead Sciences’ stock symbol?

Gilead Sciences is listed on the NASDAQ stock exchange under the ticker symbol GILD.

7. What is Gilead Sciences’ net worth?

As of the latest estimates, Gilead Sciences’ net worth is approximately $100 billion.

8. How does Gilead Sciences contribute to clinical research?

Gilead Sciences invests heavily in clinical research and has partnerships with academic institutions, research organizations, and other biopharmaceutical companies to advance the development of new therapies.

9. What is Gilead Sciences’ approach to drug pricing?

Gilead Sciences has faced criticism over the high prices of some of its drugs. The company has stated that it prices its medicines based on the value they provide to patients and society, taking into account the cost of research and development, as well as the potential benefits of the treatment.

10. How does Gilead Sciences give back to communities?

Gilead Sciences has various initiatives to support communities, including the Gilead COMPASS (Comprehensive Access Support Services) Initiative, which helps patients access HIV and hepatitis C medications, and the Gilead HIV/AIDS Research Program, which funds research to prevent and treat HIV/AIDS in underserved communities.